This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Five Best-Performing Biotech Stocks of 2013 (Some May Surprise You)

5. Keryx Biopharmaceuticals (KERX - Get Report) ^NBI Chart ^NBI data by YCharts

Keryx shares popped when the results from the Zerenex study in kidney dialysis patients were announced in January. Since then, the stock has traded mostly sideways on concerns about Keryx's ability to partner Zerenex and secure enough patent protection and market exclusivity to make the drug commercially viable.

Will these five stocks maintain their performance through the remainder of 2013? It's impossible to predict, obviously, but it's interesting to note that Clovis, Acadia and MannKind weren't Top 5 stock performers for the year at the end of the first quarter.

Three stocks that were on the list as of March 31 -- Hyperion Therapeutics (HPTX), Oramed Pharmaceuticals (ORMP) and Coronado BioSciences (CNDO) -- have dropped off.

Overall, 20 drug and biotech stocks have doubled in price this year.

A factoid that may be interesting only to me: Celsion (CLSN - Get Report) is the worst-performing drug stock year to date, but is "only" down 80%. Rounding out the bottom five: Oxygen Biotherapeutics (OXBT), Aveo Pharmaceuticals (AVEO), Genvec (GNVC) and Enzon Pharmaceuticals (ENZN).

>>To see these stocks in action, visit the Five Best-Performing Biotech Stocks of 2013 portfolio on Stockpickr.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
5 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
CHTP $0.00 0.00%
ACAD $32.59 -2.28%
CLVS $74.23 -0.96%
CLSN $2.67 -0.37%
KERX $12.73 -2.38%


DOW 17,776.12 -200.19 -1.11%
S&P 500 2,067.89 -18.35 -0.88%
NASDAQ 4,900.8850 -46.5560 -0.94%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs